ENANTA PHARMACEUTICALS, INC Proceeds From Income Tax Refund Federal
ENANTA PHARMACEUTICALS, INC (ENTA) reported Proceeds From Income Tax Refund Federal of $33.78 million for the 1-month period ending 2025-04-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIncomeTaxRefundFederal · last filed 2026-08-12
- 2025-04-30: Proceeds From Income Tax Refund Federal 1 month $33.78M.
| Period end | Proceeds From Income Tax Refund Federal 1 month |
|---|---|
| 2025-04-30 | $33.78M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |